[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-351136-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-351136-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","heterologous-prime-boost-immunization-of-aav-based-neoantigen-cancer-vaccine-induces-anti-tumor-immunity-to-inhibit-tumor-growth-and-relapse","Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse","","Therapeutic cancer vaccines that target specific antigens to induce anti-tumor immunity offer a promising cancer-treatment route. Prior work with an engineered AAV2-based neoantigen vaccine combined with radiotherapy improved tumor regression and limited distant metastasis, yet vector-based vaccination may be constrained by weak immunogenicity and vector-specific immunity. Here, AAV-based vaccination plus radiotherapy and immune checkpoint blockade enhanced responses, reduced distant metastasis risk, and showed heightened CD8+ T-cell immunogenicity with improved survival.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/heterologous-prime-boost-immunization-of-aav-based-neoantigen-cancer-vaccine-induces-anti-tumor-immunity-to-inhibit-tumor-growth-and-relapse/351136/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/heterologous-prime-boost-immunization-of-aav-based-neoantigen-cancer-vaccine-induces-anti-tumor-immunity-to-inhibit-tumor-growth-and-relapse/351136.png","ImageObject",300,407,{"name":42,"@type":43},"Rowan","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main therapeutic approach evaluated in the study?","Question",{"text":63,"@type":64},"The study evaluates heterologous prime-boost immunization using engineered AAV-based neoantigen cancer vaccines combined with local radiotherapy and immune checkpoint blockade (ICB).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why focus on poorly immunogenic cancer models?",{"text":68,"@type":64},"ICB success depends on factors such as tumor-mutational burden and tumor-infiltrating lymphocytes, and it is largely ineffective for poorly immunogenic tumors, motivating new vaccine-based strategies.",{"name":70,"@type":61,"acceptedAnswer":71},"What immune effects were observed after optimized AAV2/AAV6 vaccination?",{"text":72,"@type":64},"Optimized AAV2/AAV6 vaccination promoted CD8+ T-cell infiltration, enriched T-cell clones, and significantly decreased exhausted T-cell marker expression in tumor-infiltrating CD8+ T cells.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},351136,1790176947,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Cancer Immunology, Immunotherapy (2026) 75:86  \n[https://doi.org/10.1007/s00262-026-04336-9](https://doi.org/10.1007/s00262-026-04336-9)  \nHeterologous prime‑boost immunization of AAV‑based neoantigen cancer vaccine induces anti‑tumor immunity to inhibit tumor growth and relapse  \nChi‑Hsien Huang1,2 · Jhen‑Yu Chen3,4 · Hsin‑Yu Chang5,6 · Wei‑Ze Hong3,5 · Yi‑Wen Jiang3,5 ·  \nChien‑Yueh Lee7,8 · Chia‑Hsin Wu9 · Yu‑Sen Lin10 · Yuan‑Yao Tsai1,11 · Wei‑Ling Kao3 · KS Clifford Chao1,2,5 · Kevin Chih‑Yang Huang3,4,12,13  \nReceived: 7 November 2025 / Accepted: 9 February 2026 © The Author(s) 2026  \nAbstract  \nTherapeutic cancer vaccines, which induce anti-tumor immunity by targeting specific antigens, constitute a promising approach to cancer therapy. Our previous work developed a novel engineered adenovirus-associated virus 2 (AAV2)-based tumor-specific (neoantigen) cancer vaccine to boost antitumor immunity in combination with radiotherapy, resulting in tumor regression and less distant metastasis. However, the therapeutic efficacy of constitutive vector-based vaccination maybe limited by poor immunogenicity, pre-existing vector-specific immunity, and vaccine-induced vector-specific immunity. Here, we examined the combinational therapeutic efficacy of AAV-based cancer vaccine, local radiotherapy, and immune checkpoint blockade (ICB) in different poorly immunogenic cancer animal models. We found that administration with AAV-based neoantigen vaccine significantly increased the response to radiotherapy and ICB, and decreased the risk of distant metastasis. Furthermore, we evaluated a heterologous prime-boost immunization strategy using two optimized AAVserotype vaccines to amplify tumor-specific immunity to neoantigens. These optimized AAV2/AAV6 neoantigen vaccine displayed strong immunogenicity with potent induction of CD8+ T cells. As combined with local radiotherapy, the primeboost vaccine-induced superior tumor clearance and survival compared with other groups. Remarkably, optimized AAV2/ AAV6 vaccination promoted CD8+ T-cell infiltration in the tumors and elicited the enrichment ofT-cell clones. Furthermore, exhausted T-cell marker expression was significantly decreased in the tumor-infiltrating CD8+ T cells. Taken together, these results highlight the synergistic potency of engineered AAV2/AAV6 vaccines combined with local radiotherapy for poorly immunogenic cancers.  \nKeywords Adenovirus-associated virus · Cancer vaccine · Tumor microenvironment · Immunotherapy · Radiotherapy  \nIntroduction  \nImmune checkpoint blockade (ICB) has transformed cancer treatment strategies, highlighting the potential of immunotherapy for cancer management. However, the success of ICB therapy is highly associated with the tumor-mutational burden (TMB) and the recruitment of tumor-infiltrating lymphocytes [1, 2], making it largely ineffective for poorly immunogenic tumors such as microsatellite-stable colorectal cancer (MSS-CRC), triple-negative breast cancer (TNBC), and pancreatic adenocarcinoma (PDAC) . Indeed, clinical results indicated that ICB therapy is only effective for  \nExtended author information available on the last page of the article  \napproximately 12.5% of patients [3]. Thus, there is an urgent need to develop novel effective immunotherapeutic strategies for poorly immunogenic tumors, such as therapeutic cancer vaccine.  \nTherapeutic cancer vaccines represent a powerful immunotherapeutic approach by inducing polyclonal tumor-specific CD8+ T cells to eradicate cancer cells [4] and sensitizing poorly immunogenic tumors to ICB therapy [5–8], such as PROVENGE [9] and mRNA-based therapeutic cancer vaccines [10] . Adeno-associated virus (AAV) vectors, traditionally utilized in gene therapy for stable transgene expression in inherited diseases [11], have recently gained prominence in vaccine delivery and immunotherapy due to the discovery of new serotypes and advancements in vector bioengineering [12–14], such  \nas COVID-19 and cancer vaccine","cbCaiq5SIMevFPQP","https://ap.wps.com/l/cbCaiq5SIMevFPQP","pdf",13517981,18,"English","# Abstract\n## Introduction","[{\"question\":\"What is the main therapeutic approach evaluated in the study?\",\"answer\":\"The study evaluates heterologous prime-boost immunization using engineered AAV-based neoantigen cancer vaccines combined with local radiotherapy and immune checkpoint blockade (ICB).\"},{\"question\":\"Why focus on poorly immunogenic cancer models?\",\"answer\":\"ICB success depends on factors such as tumor-mutational burden and tumor-infiltrating lymphocytes, and it is largely ineffective for poorly immunogenic tumors, motivating new vaccine-based strategies.\"},{\"question\":\"What immune effects were observed after optimized AAV2/AAV6 vaccination?\",\"answer\":\"Optimized AAV2/AAV6 vaccination promoted CD8+ T-cell infiltration, enriched T-cell clones, and significantly decreased exhausted T-cell marker expression in tumor-infiltrating CD8+ T cells.\"}]","Heterologous prime-boost immunization of AAV-based neoantigen cancer vaccine induces anti-tumor immunity to inhibit tumor growth and relapse | PDF",1790092802,45,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/781f82abe091a827911313ec53e44ba9.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/69222f9da4bfb96b83eecca76f97a95c.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/64bee3ce289f564bf902ceab94d42cc4.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f986916a07f736de3e428ccef6ae5a2a.webp",980,1301]